iHIVARNA Clinical Trial in HIV Infected Individuals (iHIVARNA-01)

• ClinicalTrials.gov Identifier: NCT02888756
• Recruitment Status: Terminated
• First Posted: September 5, 2016
• Results First Posted: December 9, 2019
• Last Update Posted: December 23, 2019
• Sponsor: Rob Gruters
• Collaborators: Institut d'Investigacions Biomèdiques August Pi i Sunyer; IrsiCaixa; Institute of Tropical Medicine, Belgium; Vrije Universiteit Brussel; Synapse bv; Asphalion; eTheRNA immunotherapies; CR2O; Hospital Clinic of Barcelona; Germans Trias i Pujol Hospital; Universitair Ziekenhuis Brussel
• Information provided by (Responsible Party): Rob Gruters, Erasmus Medical Center

Study Description

Brief Summary:

iHIVARNA-01 is a novel therapeutic vaccine for the treatment of HIV-1-infected patients based on in vivo modification of DCs. It consists of HIVACAT-TriMix: mRNA encoding a mixture of APC activation molecules (CD40L, a constitutively active variant of TLR4 and CD70) and the HIV target antigens contained in HIVACAT to be administered through the intranodal route. iHIVARNA-01 aims to achieve the 'functional cure' of HIV infection, i.e. controlling viral replication in the absence of anti-retroviral therapy.

Condition or disease	Intervention/treatment	Phase
HIV Infections	Biological: iHIVARNA-01; Biological: TriMix; Biological: Placebo	Phase 2

Detailed Description:

Objective: To evaluate the safety and immunogenicity of iHIVARNA-01 as a new therapeutic vaccine in HIV infected patients.

Study design and duration: Phase IIa, multicentre double-blind placebo controlled intervention study. Each patient will be followed for 30 weeks. The study duration will be 38 weeks from inclusion of the first patient.

Sites: Erasmus MC, Rotterdam The Netherlands (sponsor), Hospital Clínic de Barcelona and Institut de Recerca de la Sida - Caixa, Barcelona, Spain, Instituut voor Tropische Geneeskunde Antwerp, Belgium and Vrije Universiteit Brussel/UZ Brussel, Belgium

Study population: Chronically HIV-1- infected patients under stable cART with plasma viral load (pVL) ≤ 50 copies/ml and stable CD4+ T-cell counts ≥ 450/μl, aged 18 years or above.

Sample size: after recruitment and screening, 70 patients will be included and randomized to one of the study-arms.

Intervention: One group (n=40) receives the HIVACAT-TriMix (300 microgram TriMix + 900 microgram HIVACAT) vaccine intranodally on three occasions with a two-week interval. One control group (n=15) receives TriMix only (300 microgram TriMix) and one group (n=15) receives saline intranodally on three occasions with a two-week interval. Two weeks after the last vaccination cART treatment will be interrupted. If plasma virus is detectable, cART will be re-initiated twelve weeks after treatment interruption. cART can always be re-initiated for medical reasons, as judged by the clinical investigator.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 33 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A Phase IIa Randomized, Placebo Controlled, Double Blinded Study to Evaluate the Safety and Immunogenicity of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy
• Actual Study Start Date: April 4, 2017
• Actual Primary Completion Date: February 12, 2018
• Actual Study Completion Date: February 12, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: iHIVARNA-01; Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval	Biological: iHIVARNA-01; Therapeutic vaccination, followed by treatment interruption; Other Names: HIVACAT; TriMix; Biological: TriMix; Therapeutic vaccination, followed by treatment interruption
Active Comparator: TriMix; Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval	Biological: TriMix; Therapeutic vaccination, followed by treatment interruption
Placebo Comparator: Placebo; Water for injection 3 vaccinations, two weeks interval	Biological: Placebo; Therapeutic vaccination, followed by treatment interruption

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: week 6 ]
   • Grade 3 or above local adverse event (pain, cutaneous reactions including induration).
   • Grade 3 or above systemic adverse event (temperature, chills, headache, nausea, vomiting, malaise, and myalgia).
   • Grade 3 or above other clinical or laboratory adverse event confirmed at examination or on repeat testing respectively.

   Any event attributable to vaccination leading to discontinuation of the immunisation regimen.

2. Immunogenicity as Measured by Elispot [ Time Frame: week 6 and week 18 ]
   Change from baseline immunogenicity as measured by ELISPOT at week 6 and 18, i.e. two weeks and 14 weeks after the last immunization compared to both control groups

Secondary Outcome Measures :

1. Immunogenicity as Measured by Intracellular Cytokine Staining (ICS) [ Time Frame: week 10, 18 and 30 ]
   HIV-specific CD4+ and CD8+ T cell responses after immunization by the number of poly-functional T cells as determined by intracellular cytokine staining, (ICS).
2. Time to Viral Rebound [ Time Frame: week 6-18 ]
   time until viral rebound (defined as two consecutive measurements of plasma viral load > 1000 copies/mL separated by at least 15 days) after discontinuation at week 6.
3. Change in Plasma Viral Load [ Time Frame: week 6-18 ]
   difference in log10 copies/ml plasma viral load in vivo after analytical treatment interruption (ATI, week 6-restart ART), compared to placebo WFI
4. Functional Cure [ Time Frame: week 18 ]
   proportion of patients with viral load below detectable level of 50 copies/mL in plasma after ATI, week 18
5. Primary Immune Response Against Vaccine [ Time Frame: from baseline to week 6 ]
   Change in frequency of at least 0.7log10 HIV-specific T-cell responses between baseline and week 6
6. CD8 T Cell Mediated Viral Suppression [ Time Frame: week 4 ]
   The capacity of CD8 T cells to suppress virus production in HIV infected autologous CD4 T cells, after vaccination. For this purpose PBMC are isolated and separated in CD8 and CD4 T cells. CD4 cells are infected with HIV. Thereafter CD4 cells are co-cultured with pre-stimulated CD8 cells and the capacity to suppress virus production at different effector to target (E:T) ratios is measured, by the change of p24 Gag production. Pannus et al AIDS 2019, PMID: 30702513
7. Proviral DNA Reservoir [ Time Frame: day 0-90 (week 4, week 4 + 1 day and week 5 and week 6) and day 90-130 (week 18) and day >130 (week 30) ]
   effect on reservoir as measured by changes in the proviral DNA copy numbers per million cells during and after immunization
8. Viral Immune Escape [ Time Frame: week 18 ]
   viral immune escape: change in % mutated epitopes from pre-cART to post-ATI
9. Transcriptomics [ Time Frame: week 6 and 18 ]
   host protein mRNA expression profiles in whole blood
10. Cell-associated RNA Viral Reservoir [ Time Frame: day 0-30 (week 4, week 4 + 1 day and week 5) and day 30-80 (week 6), 80-150 days (week 18) and >150 days (week 30) ]
    effect on reservoir as measured by changes in the intracellular viral RNA copy numbers per million cells during and after immunization

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. ≥ 18 years of age;
2. Voluntarily signed informed consent;
3. Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable plasma HIV-1 RNA before initiation of therapy);
4. On stable treatment with cART regimen (antiretroviral therapy consisting of at least three registered antiretroviral agents) for at least 3 years;
5. Nadir CD4+ ≥ 350 cells/μl (up to 2 occasional determinations ≤ 350 cells/μl are allowed);
6. Current CD4+ cell count ≥ 450 cells/μl;
7. HIV-RNA below 50 copies/mL in the last 6 months prior to randomization, during at least two measurements (occasional so called 'blips' ≤ 500 copies/mL are permitted);

8. If sexually active, willing to use a reliable method of reducing the risk of transmission to their sexual partners during treatment interruption (including PrEP).

   1. For heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; IUD/IUS; consistent record with condoms; physiological or anatomical sterility (in self or partner) from 14 days prior to the first vaccination until 4 months after the last vaccination.

For heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination. -

Exclusion Criteria:

1. Treatment with non-cART regimen prior to cART regimen;
2. Previous failure to antiretroviral and/or mutations conferring genotypic resistance to antiretroviral therapy;
3. Non-subtype B HIV infection;
4. Active Hepatitis B virus and/or Hepatitis C virus co-infection;
5. History of a CDC class C event (see appendix A);
6. Pregnant female (screened with a positive pregnancy test), lactating or intending to become pregnant during the study;
7. Active malignancy ≤ 30 days (extended period on the clinical assessment of the investigator) prior to screening;
8. Active infection with fever (38°C or above) ≤ 10 days of screening and/or first vaccination;
9. Therapy with immunomodulatory agents (e.g. systemic corticosteroids), including cytokines (e.g. IL-2), immunoglobulins and/or cytostatic chemotherapy ≤ 90 days prior to screening. This does not include seasonal influenza, hepatitis B and/or other travel related vaccines;
10. Congenital, acquired or induced coagulation disorders, such as thrombocytopenia (thrombocytes < 150x109/L) and/or current use of anti-coagulant medication (e.g. coumarins, inhibitors of Xa); Usage of NSAIDs (including acetylsalicylic acid) is allowed, however it is advised to interrupt therapy 10 days ahead of vaccination;
11. Usage of any investigational drug ≤ 90 days prior to study entry;
12. An employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of an employee or the investigator Any other condition, which, in the opinion of the investigator, may interfere with the evaluation of the study objectives

Contacts and Locations

Locations

Belgium

Institute for Tropical Medicine

Antwerp, Belgium

UZ Brussel

Brussels, Belgium

Netherlands

Erasmus MC

Rotterdam, Netherlands

Spain

Hospital Universitari Germans Trias i Pujol

Badalona, Spain

Hospital Clinic

Barcelona, Spain

Sponsors and Collaborators

Rob Gruters

Institut d'Investigacions Biomèdiques August Pi i Sunyer

IrsiCaixa

Institute of Tropical Medicine, Belgium

Vrije Universiteit Brussel

Synapse bv

Asphalion

eTheRNA immunotherapies

CR2O

Hospital Clinic of Barcelona

Germans Trias i Pujol Hospital

Universitair Ziekenhuis Brussel

Investigators

• Principal Investigator: Rob A Gruters, PhD; Erasmus Medical Center

  Study Documents (Full-Text)

Documents provided by Rob Gruters, Erasmus Medical Center:

Study Protocol and Statistical Analysis Plan  [PDF] April 14, 2017

More Information

Additional Information:

Description phase 1 clinical trial with iHIVARNA-01 

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R; iHIVARNA consortium. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 2019 Jun 17;20(1):361. doi: 10.1186/s13063-019-3409-1. Erratum in: Trials. 2019 Dec 13;20(1):721.

• Responsible Party: Rob Gruters, Workgroup leader, Erasmus Medical Center
• ClinicalTrials.gov Identifier: NCT02888756
• Other Study ID Numbers: iHIVARNA phase II; 2016-002724-83 ( EudraCT Number )
• First Posted: September 5, 2016
• Results First Posted: December 9, 2019
• Last Update Posted: December 23, 2019
• Last Verified: December 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Rob Gruters, Erasmus Medical Center:

Immunotherapy; mRNA; Lentivirus infection; Virus disease; Sexually transmitted disease; Immunodeficiency syndrome

Additional relevant MeSH terms:

Infections; HIV Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Immunologic Deficiency Syndromes; Immune System Diseases